TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Active, not recruitingOBSERVATIONAL
Enrollment

416

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

November 16, 2029

Study Completion Date

November 16, 2029

Conditions
Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
Trial Locations (34)

Unknown

Research Site, Aichi

Research Site, Akita

Research Site, Aomori

Research Site, Chiba

Research Site, Fukui

Research Site, Fukuoka

Research Site, Gifu

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Ishikawa

Research Site, Kagawa

Research Site, Kanagawa

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Mie

Research Site, Miyagi

Research Site, Nara

Research Site, Numakunai

Research Site, Okayama

Research Site, Osaka

Research Site, Ōita

Research Site, Saitama

Research Site, Shimane

Research Site, Shizuoka

Research Site, Tochigi

Research Site, Tokyo

Research Site, Toyama

Research Site, Wakayama

Research Site, Yamagata

Research Site, Yamaguchi

Research Site, Yamanashi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY